Data / Drug companies / Diltiazem hydrochloride
Diltiazem hydrochloride: 55 companies and 289 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Diltiazem hydrochloride is listed in the FDA National Drug Code Directory by 55 companies, with 289 products in commercial distribution. 253 of the products (87.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, extended release; tablet; tablet, extended release, and the newest product started marketing on October 1, 2026.
The request: Get every company that lists diltiazem hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 55
- Products
- 289
- Generic (ANDA) products
- 253 (87.5%)
- Application numbers
- 40
- Routes
- Oral, Intravenous
- Brand names
- Tiadylt Er, Tiazac Extended Release, Cartia XT, Cardizem La, Matzim La, Cardizem CD, Cardizem, Cartia XT
- openFDA record search
- api.fda.gov
Companies that list diltiazem hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 25 | capsule, extended release; capsule, coated, extended release | Generic drugs (ANDA) | September 26, 2022 |
| Bausch Health US LLC | 20 | capsule, extended release; tablet, extended release | New drug applications (NDA) | August 20, 2014 |
| Zydus Lifesciences Limited | 15 | capsule, extended release; tablet | Generic drugs (ANDA) | May 25, 2026 |
| Oceanside Pharmaceuticals | 14 | capsule, extended release; tablet | Authorized generics (NDA) | August 20, 2014 |
| Alembic Pharmaceuticals Inc. | 12 | capsule, extended release; tablet, film coated | Generic drugs (ANDA) | November 14, 2025 |
| Alembic Pharmaceuticals Limited | 12 | capsule, extended release; tablet, film coated | Generic drugs (ANDA) | November 14, 2025 |
| Zydus Pharmaceuticals USA Inc. | 11 | capsule, extended release | Generic drugs (ANDA) | November 8, 2017 |
| ScieGen Pharmaceuticals, Inc. | 10 | tablet, extended release; tablet | Generic drugs (ANDA) | April 6, 2023 |
| Sun Pharmaceutical Industries, Inc. | 10 | capsule, extended release | Generic drugs (ANDA) | October 31, 2011 |
| Slate Run Pharmaceuticals, LLC | 9 | tablet, extended release; capsule, extended release | Generic drugs (ANDA) | March 20, 2023 |
| Ingenus Pharmaceuticals, LLC | 8 | capsule, extended release | Generic drugs (ANDA) | July 3, 2025 |
| Upsher-Smith Laboratories, LLC | 8 | capsule, extended release | Generic drugs (ANDA) | May 1, 2023 |
| A-S Medication Solutions | 7 | capsule, extended release; tablet | Generic drugs (ANDA) | September 26, 2022 |
| American Health Packaging | 6 | capsule, coated, extended release; tablet, film coated | Generic drugs (ANDA) | December 8, 2023 |
| Bryant Ranch Prepack | 6 | capsule, coated, extended release; capsule, extended release | Generic drugs (ANDA) | October 1, 2015 |
| Cipla USA Inc. | 6 | tablet, extended release | Generic drugs (ANDA) | June 12, 2023 |
| Hikma Pharmaceuticals USA Inc. | 6 | injection | Generic drugs (ANDA) | December 17, 2008 |
| Actavis Pharma, Inc. | 5 | tablet, extended release | Generic drugs (ANDA) | March 28, 2011 |
| Golden State Medical Supply, Inc. | 5 | capsule, extended release | Generic drugs (ANDA) | June 14, 2019 |
| Macleods Pharmaceuticals Limited | 5 | capsule, extended release | Generic drugs (ANDA) | June 23, 2023 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 5 | capsule, extended release; tablet, film coated | Generic drugs (ANDA) | June 14, 2019 |
| Actavis Pharma, Inc. | 4 | capsule, extended release | Generic drugs (ANDA) | July 9, 1998 |
| Chartwell RX, LLC | 4 | tablet | Generic drugs (ANDA) | November 5, 1992 |
| Golden State Medical Supply, Inc. | 4 | capsule, extended release | Generic drugs (ANDA) | August 30, 2018 |
| Major Pharmaceuticals | 4 | capsule, extended release | Generic drugs (ANDA) | August 9, 2022 |
| Teva Pharmaceuticals USA, Inc. | 4 | tablet, film coated | Generic drugs (ANDA) | December 26, 1995 |
| Viona Pharmaceuticals Inc | 4 | tablet | Generic drugs (ANDA) | May 25, 2026 |
| Accord Healthcare Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | September 11, 2020 |
| Apotex Corp. | 3 | capsule, extended release | Generic drugs (ANDA) | July 30, 2001 |
| AvKARE | 3 | capsule, extended release | Generic drugs (ANDA) | April 3, 2025 |
| Cardinal Health 107, LLC | 3 | capsule, extended release | Generic drugs (ANDA) | August 1, 2023 |
| Coupler LLC | 3 | tablet; capsule, extended release | Generic drugs (ANDA) | May 1, 2025 |
| Cranbury Pharmaceuticals, LLC | 3 | capsule, extended release | Generic drugs (ANDA) | October 1, 2026 |
| Dr. Reddy's Laboratories Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | September 10, 2024 |
| Eugia US LLC | 3 | injection, solution | Generic drugs (ANDA) | March 29, 2023 |
| Glenmark Pharmaceuticals Inc., USA | 3 | capsule, extended release | Generic drugs (ANDA) | March 22, 2021 |
| Mylan Institutional Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | December 15, 1999 |
| Mylan Pharmaceuticals Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | May 2, 1997 |
| NorthStar Rx LLC | 3 | capsule, extended release | Generic drugs (ANDA) | February 22, 2022 |
| NuCare Pharmaceuticals,Inc. | 3 | capsule, extended release; tablet | Generic drugs (ANDA) | December 25, 2010 |
| Safecor Health, LLC | 3 | capsule, extended release | Generic drugs (ANDA) | February 2, 2026 |
| Medical Purchasing Solutions, LLC | 2 | injection; injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Northwind Health Company, LLC | 2 | tablet | Generic drugs (ANDA) | January 18, 2024 |
| Remedyrepack Inc. | 2 | capsule, extended release | Generic drugs (ANDA) | August 19, 2022 |
| WG Critical Care, LLC | 2 | injection, solution | New drug applications (NDA) | March 21, 2025 |
| Actavis Pharma, Inc. | 1 | capsule, extended release | Generic drugs (ANDA) | November 25, 2013 |
| Direct_Rx | 1 | capsule, extended release | Generic drugs (ANDA) | April 6, 2022 |
| HF Acquisition Co LLC, DBA HealthFirst | 1 | injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Hospira, Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 30, 2005 |
| Northwind Health Company, LLC | 1 | tablet, film coated | Generic drugs (ANDA) | August 11, 2022 |
| Preferred Pharmaceuticals Inc. | 1 | capsule, extended release | Generic drugs (ANDA) | February 15, 2021 |
| ProPharma Distribution | 1 | injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Proficient Rx LP | 1 | tablet, film coated | Generic drugs (ANDA) | December 26, 1995 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Sun Pharmaceutical Industries, Inc. | 1 | capsule, extended release | Generic drugs (ANDA) | October 31, 2018 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, extended release | 173 | 59.9% |
| Tablet | 29 | 10% |
| Tablet, extended release | 29 | 10% |
| Tablet, film coated | 20 | 6.9% |
| Capsule, coated, extended release | 18 | 6.2% |
| Injection, solution | 9 | 3.1% |
| Injection | 7 | 2.4% |
| Tablet, coated | 3 | 1% |
| Injection, powder, lyophilized, for solution | 1 | 0.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 253 | 87.5% |
| New drug applications (NDA) | 22 | 7.6% |
| Authorized generics (NDA) | 14 | 4.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Calcium Channel Blocker | 289 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.